DBV Technologies (NASDAQ:DBVT) Shares Gap Down – What’s Next?

DBV Technologies S.A. (NASDAQ:DBVT)’s stock price gapped down prior to trading on Thursday. The stock had previously closed at $11.76, but opened at $11.30. DBV Technologies shares last traded at $11.32, with a volume of 90,769 shares changing hands.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on DBVT. Citigroup restated a “market outperform” rating on shares of DBV Technologies in a report on Wednesday. Weiss Ratings cut shares of DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating on shares of DBV Technologies in a research report on Tuesday, June 30th. Cantor Fitzgerald reiterated an “overweight” rating on shares of DBV Technologies in a report on Thursday, September 10th. Finally, Citizens Jmp upped their price target on DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a research note on Tuesday, June 30th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $48.50.

DBV Technologies Trading Down 5.4%

The business has a 50 day simple moving average of $13.36 and a two-hundred day simple moving average of $16.64. The stock has a market cap of $699.79 million, a price-to-earnings ratio of -3.17 and a beta of -0.95.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada grew its holdings in DBV Technologies by 167.1% during the 1st quarter. Royal Bank of Canada now owns 4,680 shares of the company’s stock worth $98,000 after acquiring an additional 2,928 shares in the last quarter. Cetera Investment Advisers lifted its position in shares of DBV Technologies by 93.4% during the first quarter. Cetera Investment Advisers now owns 25,358 shares of the company’s stock worth $530,000 after purchasing an additional 12,243 shares during the last quarter. Personal CFO Solutions LLC acquired a new position in DBV Technologies in the first quarter worth about $264,000. AdvisorShares Investments LLC acquired a new position in DBV Technologies in the first quarter worth about $1,052,000. Finally, Diversify Wealth Management LLC bought a new stake in DBV Technologies in the first quarter valued at about $1,293,000. 71.74% of the stock is currently owned by institutional investors.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s lead technology, Viaskin, is designed to deliver targeted immunotherapy through the skin without requiring an injection. Its approach is intended to expose the immune system to controlled amounts of an allergen while limiting systemic exposure.

DBV Technologies’ primary product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.